Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)

BACKGROUND: Inhibitors of the anaplastic lymphoma kinase (ALK) gene mutation are highly effective treatments for ALK-positive lung cancer. We conducted this pharmacovigilance analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS). PATIENTS AND METHODS: FAERS files fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Omar, N.E., Fahmy Soliman, A.I., Eshra, M., Saeed, T., Hamad, A., Abou-Ali, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649649/
https://www.ncbi.nlm.nih.gov/pubmed/34864500
http://dx.doi.org/10.1016/j.esmoop.2021.100315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649649/
https://www.ncbi.nlm.nih.gov/pubmed/34864500
http://dx.doi.org/10.1016/j.esmoop.2021.100315

Ejemplares similares